The size of the MEA RNAi Drug Delivery market is estimated to reach USD 14.94 billion by 2027 from a market value of USD 5.33 billion in 2022, at a CAGR of 22.88%.
RNAi Drug Delivery means sending artificial drugs into our body to inhibit gene expression and preventing cancerous cells to increase. RNAi drugs are used to cure various chronic diseases. Right now, Research is being carried out to find right genes to cure cancer. This market has high potential in the near future.
Few factors like Increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Middle East and Africa RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Availability of advanced technology here compared to developed regions is low which is restraining the market’s growth.
Middle East and Africa RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.
Based on Geography, this market is further segmented into Middle East and Africa. CAGR is low here compared to other regions because of lack of advanced research facilities and major nations around here.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug delivery
5.1.1 Introduction
5.1.2 nanoparticle drug delivery technology
5.1.3 pulmonary drug delivery technology
5.1.4 nucleic acid drug delivery technology
5.1.5 aptamer drug delivery technology
5.1.6 Y-o-Y Growth Analysis, By Drug Delivery
5.1.7 Market Attractiveness Analysis, By Drug delivery
5.1.8 Market Share Analysis, By drug Delivery
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 infectious diseases
5.2.3 cardiology
5.2.4 oncology
5.2.5 neurology
5.2.6 ophthalmology
5.2.7 metabolic disorders
5.2.8 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.9 Market Attractiveness Analysis, By Therapeutic Application
5.2.10 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Delivery
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Delivery
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Delivery
6.1.5.3 By Therapeutic Application
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alnylam Pharmaceuticals Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co. Inc
8.3 Access Pharmaceuticals Inc.
8.4 Dicerna Pharmaceuticals Inc.
8.5 Tekmira Pharmaceuticals Corp.
8.6 Isis Pharmaceuticals Inc
8.7 Calondo Pharmaceuticals Inc.
8.8 Marina Biotech Inc.
8.9 RXi Pharmaceuticals Corp
8.10 Quark Pharmaceuticals Inc
8.11 Silence Therapeutics plc
8.12 Traversa Therapeutics Inc.
8.13 Tacere Therapeutics Inc
8.14 Sirnaomics Inc.
8.15 PhaseRx Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
